Jan 6 2011
Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, and Ortho Dental Solutions LTD (Tel Aviv, Israel) today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant Ortho Dental Solutions LTD rights to patent application and knowhow for use in developing novel therapies limited in use for dental and gum diseases.
Under this agreement, ODS will use Enox Biopharma technologies to develop an innovative treatment for Periodontal disease. Enox formulation has been proven as an effective agent against a wide range of bacterial infections and ODS will use the formulation to develop novel products in order to reduce post dental treatment infections and to prevent periodontal disease.
Periodontal disease remains one of the most common diseases throughout the world which, if left untreated, can lead to tooth loss. Periodontal disease is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease can affect one tooth or many teeth. Periodontal disease is associated with biofilm and its formation that causes the gums to become inflamed and infected.
Prof. David Greenberg, M.D., Enox Biopharma Chief Medical Officer, stated, "We are very pleased with this agreement which valued our technology and further develops our franchise in dental diseases that affect millions of patients worldwide. Periodontal diseases, and Gingivitis in particular, is a serious public health problem that requires effective and well tolerated treatment in order to significantly decrease the prevalence of the disease."
Prof. Herbert Judes, M.D., Ortho Dental Solutions Chief Executive Officer, stated, "Periodontal diseases is today one of the most common diseases in the world. Forty percent of the population suffers from dental disease, the main cause of which is potential pathogens that are found in our mouths. A large part of the population will lose their teeth due to these infections. We believe that by using the Enox formulation we can develop better solutions for conservative treatment and control of periodontal disease."